Last reviewed · How we verify
Trehalose for IV Infusion
At a glance
| Generic name | Trehalose for IV Infusion |
|---|---|
| Sponsor | Bioblast Pharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. (PHASE1)
- STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia (PHASE2, PHASE3)
- SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease (PHASE2)
- Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose (PHASE2)
- Continuation Protocol to Protocol BBCO-001 (PHASE3)
- A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trehalose for IV Infusion CI brief — competitive landscape report
- Trehalose for IV Infusion updates RSS · CI watch RSS
- Bioblast Pharma Ltd. portfolio CI